Cerus grants 264,000 RSUs to chief medical officer

Cerus Corp’s chief medical officer, Benjamin Richard J, reported an equity grant on Form 4.

Accepted by SEC EDGAR 03/04/2026 - 08:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cerus Corp’s chief medical officer, Benjamin Richard J, reported an equity grant on Form 4. On March 2, 2026, he acquired 264,000 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he directly holds 949,775 common shares. Each RSU converts into one share and vests in two installments: 34% on March 12, 2027 and 66% on March 12, 2028, subject to his continuous service with Cerus through each vesting date.

Insider Trade Summary

Grant/Award: 264,000 shares

Grant/Award 1 txn

Insider Benjamin Richard J

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	264,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 949,775 shares (Direct)

Holdings Before and After: Common Stock, 685,775 to 949,775 shares (Direct)

Footnotes (1)

1. F1. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest in two annual installments with 34% of the grant vesting on March 12, 2027, and 66% of the grant vesting on March 12, 2028, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cerus (CERS) report for its chief medical officer?

Cerus reported an equity award to its chief medical officer on Form 4. On March 2, 2026, he received 264,000 restricted stock units of Cerus common stock at a stated price of $0.00 per share, increasing his direct holdings to 949,775 shares.

How many RSUs were granted to Cerus (CERS) chief medical officer Benjamin Richard J?

Benjamin Richard J received a grant of 264,000 restricted stock units. Each RSU represents the right to receive one share of Cerus common stock, so the award, once fully vested and settled, could add 264,000 shares to his beneficial holdings, subject to vesting conditions.

What is the vesting schedule for the 264,000 Cerus (CERS) RSUs granted to the CMO?

The 264,000 RSUs vest in two annual tranches. According to the filing, 34% of the grant vests on March 12, 2027, and the remaining 66% vests on March 12, 2028, assuming continuous service with Cerus through each vesting date.

Are the Cerus (CERS) RSUs granted to the chief medical officer subject to service conditions?

Yes, the RSUs are service-based awards. The filing states vesting occurs only if the chief medical officer maintains continuous service with Cerus through March 12, 2027 for the first tranche and March 12, 2028 for the second, larger tranche.

How many Cerus (CERS) shares does the chief medical officer own after this RSU grant?

After the reported grant, the chief medical officer directly holds 949,775 shares of Cerus common stock. This total reflects his ownership immediately following the award of 264,000 restricted stock units reported in the Form 4 transaction data.

Does the Cerus (CERS) Form 4 indicate a stock purchase or an equity award?

The Form 4 indicates an equity award, not an open-market purchase. The transaction is coded as a grant or award acquisition (code A), with 264,000 shares acquired at $0.00 per share in the form of restricted stock units subject to future vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Benjamin Richard J

(Last) (First) (Middle)

C/O CERUS CORPORATION

1220 CONCORD AVE SUITE 600

(Street)

CONCORD CA 94520

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CERUS CORP [ CERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A(1)		264,000	A	$0	949,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest in two annual installments with 34% of the grant vesting on March 12, 2027, and 66% of the grant vesting on March 12, 2028, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

	Richard J. Benjamin, by Chrystal N. Jensen, attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.